Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,144 public trials 2,036 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Norwalk Hospital-oncology Norwalk, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 216 locations
View Trial Details
Active, not recruiting

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642

Conditions
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, +13 more
Locations
  • Research Site Tampa, Florida, United States
  • Research Site Louisville, Kentucky, United States
  • Research Site New Brunswick, New Jersey, United States
  • Research Site Charlotte, North Carolina, United States
View all 25 locations
View Trial Details
Active, not recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Krankenhaus der Barmherzigen Brüder Graz - Abteilung Für Innere Medizin I Graz, Austria
  • Krems University Hospital - Abteilung Für Innere Medizin 2 Krems, Austria
  • LKH HOCHSTEIERMARK - Department für Hämato-Onkologie Leoben, Austria
  • Kepler Universitaetsklinikum - Univ.-Klinik für Hämatologie und Internistische Onkologie Linz, Austria
View all 111 locations
View Trial Details
Active, not recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, not recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCI Health Laguna Hills Laguna Hills, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 27 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0046 Mobile, Alabama, United States
  • Local Institution - 0005 Cerritos, California, United States
  • Local Institution - 0190 Irvine, California, United States
  • Local Institution - 0187 Los Angeles, California, United States
View all 204 locations
View Trial Details
Active, not recruiting

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

NCT04981899

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • National Medicine Research Center of oncology named after N.N. Petrov Saint Petersburg, Pesochny, Russia
  • Irkutsk Regional Cancer Center Irkutsk, Russia
  • St. Petersburg State Pavlov Medical University Saint Petersburg, Northwestern Federal District, Russia
View Trial Details

Related conditions